Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression VANCOUVER, BC, Oct. 13, 2021 /CNW/ – MYND Diagnostics Inc., a wholly-owned subsidiary of MYND Life Sciences (CSE: MYND) (OTC: MYNDF) is pleased to announce that the Company’s proprietary biomarker test technology will be a pivotal component of a proposed clinical trial seeking partial funds from a $15…


Previous articleNuminus Upgrades Psychedelics Lab to Increase Research Service Capabilities
Next articlePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome